[go: up one dir, main page]

FR2889533B1 - Anticorps diriges contre le recepteur du ldl - Google Patents

Anticorps diriges contre le recepteur du ldl

Info

Publication number
FR2889533B1
FR2889533B1 FR0508282A FR0508282A FR2889533B1 FR 2889533 B1 FR2889533 B1 FR 2889533B1 FR 0508282 A FR0508282 A FR 0508282A FR 0508282 A FR0508282 A FR 0508282A FR 2889533 B1 FR2889533 B1 FR 2889533B1
Authority
FR
France
Prior art keywords
antibodies against
ldl receptor
against ldl
receptor
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0508282A
Other languages
English (en)
Other versions
FR2889533A1 (fr
Inventor
Christian Behrens
Christine Gaucher
Jean Francois Prost
Jamila Najib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0508282A priority Critical patent/FR2889533B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to EP06794206A priority patent/EP1919953A1/fr
Priority to CA002618044A priority patent/CA2618044A1/fr
Priority to AU2006274751A priority patent/AU2006274751A1/en
Priority to US11/989,821 priority patent/US20090175789A1/en
Priority to PCT/FR2006/001806 priority patent/WO2007014991A1/fr
Priority to JP2008524538A priority patent/JP2009502188A/ja
Publication of FR2889533A1 publication Critical patent/FR2889533A1/fr
Application granted granted Critical
Publication of FR2889533B1 publication Critical patent/FR2889533B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR0508282A 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl Expired - Fee Related FR2889533B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0508282A FR2889533B1 (fr) 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl
CA002618044A CA2618044A1 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl
AU2006274751A AU2006274751A1 (en) 2005-08-03 2006-07-25 Antibodies directed against a LDL receptor
US11/989,821 US20090175789A1 (en) 2005-08-03 2006-07-25 Antibody raised against the ldl receptor
EP06794206A EP1919953A1 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl
PCT/FR2006/001806 WO2007014991A1 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl
JP2008524538A JP2009502188A (ja) 2005-08-03 2006-07-25 Ｌｄｌ受容体に対する抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508282A FR2889533B1 (fr) 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl

Publications (2)

Publication Number Publication Date
FR2889533A1 FR2889533A1 (fr) 2007-02-09
FR2889533B1 true FR2889533B1 (fr) 2007-10-12

Family

ID=35891109

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0508282A Expired - Fee Related FR2889533B1 (fr) 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl

Country Status (7)

Country Link
US (1) US20090175789A1 (fr)
EP (1) EP1919953A1 (fr)
JP (1) JP2009502188A (fr)
AU (1) AU2006274751A1 (fr)
CA (1) CA2618044A1 (fr)
FR (1) FR2889533B1 (fr)
WO (1) WO2007014991A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543074A (ja) * 2006-07-07 2009-12-03 スカイフック ワイヤレス，インク． Ｗｌａｎ測位装置の位置を推定するためにｗｌａｎ対応アクセス・ポイントから情報を収集するシステム及び方法
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
CA2801184A1 (fr) * 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Anticorps anti-sparc du sang peripherique et leurs utilisations
US20120046429A1 (en) 2010-08-23 2012-02-23 Fina Technology, Inc. Sequential Formation of Ziegler-Natta Catalyst Using Non-blended Components
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
AR096601A1 (es) * 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
WO2016097175A1 (fr) * 2014-12-18 2016-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveau procédé de traitement du cancer du pancréas
WO2018089300A1 (fr) 2016-11-10 2018-05-17 Merck Sharp & Dohme Corp. Ligand ilt3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法
IL139217A0 (en) * 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
JP2004529080A (ja) * 2000-10-25 2004-09-24 アグネッロ，ヴィンセント Ｈｃｖ、他のフラビウイルス科ウイルス、および血液中で低密度リポタンパク質または超低密度リポタンパク質と複合体を形成するその他のあらゆるウイルスによる感染を細胞中へのウイルス侵入を抑制することによって防止する方法
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins

Also Published As

Publication number Publication date
US20090175789A1 (en) 2009-07-09
AU2006274751A8 (en) 2008-04-10
FR2889533A1 (fr) 2007-02-09
CA2618044A1 (fr) 2007-02-08
AU2006274751A1 (en) 2007-02-08
WO2007014991A1 (fr) 2007-02-08
JP2009502188A (ja) 2009-01-29
EP1919953A1 (fr) 2008-05-14

Similar Documents

Publication Publication Date Title
EP2211903A4 (fr) Anticorps anti-cll-1
EP1964852A4 (fr) Anticorps anti-ilt7
EP2121751A4 (fr) Anticorps monoclonaux dirigés contre angptl3
EP2142214A4 (fr) Anticorps anti-ige
EP2102238A4 (fr) Anticorps anti-cd44
EP1853313A4 (fr) Anticorps humanises l243
EP2220247A4 (fr) Anticorps dirigés contre lrp6
EP2172483A4 (fr) ANTICORPS ANTI-Muc17
EP2011869A4 (fr) Nouvel anticorps anti-cd98
EP2006379A4 (fr) Anticorps bispecifique hautement fonctionnel
EP2076614A4 (fr) Anticorps synthetiques
ITBO20050495A1 (it) Elettrocatetere esogageo
EP2324359A4 (fr) Anticorps monoclonal stro-4
EP2262831A4 (fr) Anticorps anti-properdine
DK2902690T3 (da) Anomalidetektor til rørledninger
DE602005014129D1 (de) Rohrleitung
EP1877075A4 (fr) Anticorps diriges contre la myostatine
EP1942028A4 (fr) Siège
DK2278284T4 (da) Vejeanordning
EP1944192A4 (fr) Siège
BRPI0715705A2 (pt) bateria
EP2212431A4 (fr) Anticorps anti-irem-1
DE602007000311D1 (de) Sitzstützstruktur
DE602007001626D1 (de) Schwingförderer
ITMI20061101A1 (it) Gattuccio

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse

Effective date: 20140430